For private equity sponsors and operators of cell and gene therapy businesses

Programs, indications, treatment sites and manufacturing capacity all rise. Patient access, treatment capacity, cycle time and cash do not move with them.

The constraint is rarely one workflow or one technology. It is the interaction among patient identification, site readiness, collection, manufacturing, chain of custody, product release and reimbursement.

What grows Programs · indications · treatment centers · manufacturing slots · geographies · partners
What should follow Completed treatments · faster site activation · shorter cycle time · reliable release · collected cash
Six leverage domains Where scale should create leverage, and why it usually does not.
Portfolio and launch readiness
Launches that reuse existing capability.
Each therapy runs as a separate program with its own infrastructure.
Patient identification and access
Eligible patients reach an authorized decision.
Referral, eligibility, benefit verification and scheduling stay fragmented.
Center readiness and capacity
Faster activation, better use of scarce clinical capacity.
Training, apheresis, pharmacy, bed and lab readiness are managed separately.
Collection-to-administration
A predictable journey with reliable chain of identity and custody.
Milestones depend on manual coordination across several organizations.
Manufacturing and release
Predictable release, lower cost per successful treatment.
Starting-material variability, testing and exception handling create rework.
Revenue, quality and integration
Timely reimbursement, collected cash, consistent performance.
Contracting, authorization, outcomes and quality systems remain fragmented.
The answer is not automatically more technology
The right intervention may be simplification, standardization, a shared capability, better system linkage, conventional automation or selective AI. The objective is the simplest intervention capable of changing the economics.
SCALED · how far the intervention should go An organization may stop at any stage.
S Simplify→ C Codify→ A Aggregate→ L Link→ E Execute automatically→ D Deploy AI selectively
Two decades inside regulated healthcare operations: 30+ regulated products shipped, P&L-owner. Ex-LabCorp, Deployed systems to the VA, NHS, Memorial Sloan-Kettering.
Start with one consequential question
One question involving patient access, site readiness, treatment capacity, orchestration, manufacturing, margin or cash. A preliminary conversation determines whether it warrants a diagnostic.
Discuss a cell and gene therapy value-creation question →
Arvita Tripati
Value Creation Advisor & CEO, Vahana Labs
arvita@vahanalabs.ai